Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2008-02-07
2010-02-16
Gambel, Phillip (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S130100, C424S133100, C424S138100, C424S141100, C424S174100, C424S178100, C424S181100, C530S387100, C530S387300, C530S387700, C530S388100, C530S388200, C530S391100, C530S391700, C435S069600
Reexamination Certificate
active
07662383
ABSTRACT:
The invention relates to murine monoclonal antibodies (MAbs), A, B, C and D, which are directed against tumor-associated antigens. The nearly complete nucleotide sequences of the V genes of these MAbs are described, so that the relevant variable domains can be put together to give chimeric MAbs, or “humanized” MAbs are obtained by inserting the hypervariable regions (complementarity determining regions=CDR) into a human MAb framework. Antibody constructs of this type can be employed in human therapy and in vivo diagnosis without the disadvantages observed with murine MAbs.
REFERENCES:
patent: 3862925 (1975-01-01), Sarantakis et al.
patent: 4331647 (1982-05-01), Goldenberg
patent: 4349528 (1982-09-01), Koprowski et al.
patent: 4444744 (1984-04-01), Goldenberg
patent: 4446240 (1984-05-01), Nerenberg
patent: 4460561 (1984-07-01), Goldenberg
patent: 4485093 (1984-11-01), Runge
patent: 4522918 (1985-06-01), Schlom et al.
patent: 4569788 (1986-02-01), Mulshine et al.
patent: 4579827 (1986-04-01), Sakamoto et al.
patent: 4582797 (1986-04-01), Trowbridge
patent: 4585742 (1986-04-01), Bernal
patent: 4612282 (1986-09-01), Schlom et al.
patent: 4645828 (1987-02-01), Twardzik et al.
patent: 4677058 (1987-06-01), Tryggvason et al.
patent: 4683200 (1987-07-01), Hirohashi et al.
patent: 5169939 (1992-12-01), Gefter et al.
patent: 5204244 (1993-04-01), Fell et al.
patent: 5354847 (1994-10-01), Liu et al.
patent: 6926896 (2005-08-01), Bosslet et al.
patent: 3329184 (1985-02-01), None
patent: A 0098162 (1984-01-01), None
patent: 0141079 (1984-08-01), None
patent: A 0118365 (1984-09-01), None
patent: A 0141079 (1985-05-01), None
patent: 0145373 (1985-06-01), None
patent: 0151030 (1985-08-01), None
patent: A 0153114 (1985-08-01), None
patent: 0160897 (1985-11-01), None
patent: A 0160446 (1985-11-01), None
patent: 0171083 (1986-02-01), None
patent: 0189849 (1986-08-01), None
patent: A 0213581 (1987-03-01), None
patent: 0268468 (1988-05-01), None
patent: 0365209 (1990-04-01), None
patent: 0368684 (1990-05-01), None
patent: 0411893 (1991-02-01), None
patent: 1193378 (1970-05-01), None
patent: WO 81/01469 (1981-05-01), None
patent: WO 88/02117 (1988-03-01), None
Accolla, R. et al., “Monoclonal Antibodies Specific for Carcinoembryonic Antigen and Produced by Two Hybrid Cell Lines,”Proc. Natl. Acad. Sci. USA, 77:563-66 (1980).
Benz, P. et al., “Monoclonal Antibody BW 431/26 Labeled with Technetium 99m and Indium 111: an Investigation of the Biodistribution and the Diosimetry in Patients,” 18(10):813-16 (1991).
Bosslet, K. et al., “Molecular Characteristics of Two Lung Carcinoma Cell-Line Associated Membrane Antigens,”Behring Inst. Mitt, 74:27-34 (1984).
Bosslet, K. et al, “Monoclonal Murine Antibodies with Specificity for Tissue Culture Lines of Human Squamous-Cell Carcinoma of the Lung,”Cancer Detection and Prevention, 6:181-84 (1983).
Bosslet, K. et al., “Immunological Tailoring of Monoclonal-Antibodies (MAB) Suited for Immunotherapy of Pancreatic-Carcinoma,”Br. J. Cancer, 56:516 (1987).
Brown, J. et al., “A Microassay for Antibody Binding to Tumor Cell Surface Antigens Using125I-Labeled Protein A fromStaphylococcus aureus,” J. Immunological Methods, 15:57-66 (1977).
Cahan, L. et al., “Identification of a Human Neuroectodermal Tumor Antigen (OFA-I-2) as Ganglioside GD2,”Proc. Natl. Acad. Sci. USA, 79:7629-33 (1982).
Campbell,Monoclonal Antibody Technology, Chapters 3, 4, and 6 to 10 (Elsevier), 1985.
Chin, J. et al., “Detection of Human Pancreatic Adenocarcinomas by Histochemical Staining with Monoclonal Antibody,”Cancer Research, 45:1723-29 (1985).
Conchie, J. et al., “Mammalian Glycosidases, Distribution in the Body,”Biochem., 71:318-25 (1959).
Cuttitta, F. et al., “Monoclonal Antibodies that Demonstrate Specificity for Several Types of Human Lung Cancer,”Proc. Nat'l. Acad. Sci. USA, 78:4591-95 (1981).
Davies, P. et al., “The Quantitative Estimation of Pinocytosis Using Radioactive Colloidal Gold,”Biochem. and Biophys. Res. Comm., 52:627-34 (1973).
Dillman, R.O., “Monoclonal Antibodies for Treating Cancer,”Ann. Internal Med., 111:592-603 (1989).
Hand, P.H. et al., “Influence of Spatial Configuration of Carcinoma Cell-Populations on the Expression of a Tumor-Associated Glycoprotrein,”Cancer Research, 45:833-40 (1985).
Harris, W.J. et al., “Therapeutic Antibodies—The Coming of Age,”TIBTECH, 11:42-46 (1993).
Herlyn, D. et al., “Inhibition of Human Tumor Growth by IgG2a Monoclonal Antibodies Correlates with Antibody Density on Tumor Cells,”J. Immunology, 134:1300-04 (1985).
Heyderman, E., “Immunoperoxidase Technique in Histopathology: Applications, Methods and Controls,”J. Clinical Pathology, 32:971-78 (1979).
Hird et al.,Genes and Cancer, Wiley & Sons Ltd. 17, ed. Carnet et al. (1990).
Houghton, A. et al., “Surface Antigens of Melanocytes and Melanomas,”J. Exp. Med., 156:1755-66 (1982).
Johnson, J. et al., “Surface Antigens of Human Melanoma Cells Defined by Monoclonal Antibodies, I. Biochemical Characterization of Two Antigens Found on Cell Lines and Fresh Tumors of Diverse Tissue Origin,”Eur. J. Immuno., 11:825-31 (1981).
Klapdor, R. et al., “Experimental and Clinical Studies with the New Monoclonal Antibody 494132 in Pancreatic Carcinomas,”Digestion, 35(1):31 (1986).
Kohler, G. et al., “Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity,”Nature, 256:495-7 (1975).
Kohler, G. et al., “Derivation of Specific Antibody-Producing Tissue Culture and Tumor Lines by Cell Fusion,” Eur.J. Immunol., 6:511-19 (1976).
Kubel, R. et al., “Immunotherapy of Pancreatic-Cancer with the Monoclonal-Antibody BW 494/32—Preliminary-Results of a Phase I/II Clinical -Trial,”Br. J. Cancer, 56:528 (1987).
Lieber, M. et al., “Establishment of a Continuous Tumor-Cell Line (PANC-1) From a Human Carcinoma of the Exocrine Pancreas,”Int. Cancer, 15:741-47 (1975).
Lind, P. et al., “Anti-Carcinoembryonic Antigen Immunoscintigraphy (Technetium-99m-Monoclonal Antibody BW 431/26) and Serum CEA Levels in Patients with Suspected Primary and Recurrent Colorectal Carcinoma,”The Journal of Nuclear Medicine, 32(7):1319-25 (1991).
Lind, P. et al. “Immunoscintigraphy of Inflammatory Processes with a Technetium-99m-Labeled Monoclonal Antigranulocyte Antibody (MAb BW 250/183),” 31(4):417-23 (1990).
Loop, S. et al., “Human Tumor-Associated Antigens, p155 and p210, Detected by Monoclonal Antibodies,”Biological Abstracts, vol. 73, Heft 1, 1982, p. 431, col. 2, Abstract No. 4132; Abstract,Int. J. Cancer, 27:775-82 (1981).
Lutz, R. et al., “Reshaping Human Antibodies for Therapy,”Nature, 332:323-27 (1988).
Magnani, J.L. et al., “Identification of the Gastrointestinal and Pancreatic Cancer-Associated Antigen Detected by Monoclonal Antibody 19-9 in the Sera of Patients as a Mucin,”Cancer Research, 43:5489-92 (1983).
Meeting Highlights, “Breast Cancer, Epithelial Cells, and Extracellular Matrix,”JNCI, 73:999-1001 (1984).
Mitchell, K., “A Carcinoembryonic Antigen (CEA) Specific Monoclonal Hybridoma Antibody that Reacts only with High-Molecular-Weight CEA,”Chemical Abstracts, 94:577, Abstract No. 137538s (1981).
Morrison-Plummer, J. et al., “An ELISA to Detect Monoclonal Antibodies Specific for Lipid Determinants ofMycoplasma pneumoniae,” Journal of Immunological Methods, 64:165-78 (1983).
Osband, M.E. et al., “Problems in the Investigational Study and Clinical Use of Cancer Immunotherapy Immunology Today,”Immunotherapy, 11:193-95 (1990).
Saiki, R.K. et al., “Enzymatic Amplification of β-Globin Genomic Sequences and Restriction Site Analysis for Diagnosis of Sickle Cell Anemia,”Science230:1350-54 (1985).
Saito, M. et al., “Gangli
Auerbach Bernhard
Bosslet Klaus
Sedlacek Hans Harald
Seemann Gerhard
Aventis Pharma Deutschland GmbH
Finnegan Henderson Farabow Garrett & Dunner LLP
Gambel Phillip
LandOfFree
Chimeric antibody against tumor associated antigens and its... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chimeric antibody against tumor associated antigens and its..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chimeric antibody against tumor associated antigens and its... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4196520